Background and aim: Hepatitis C virus (HCV) clearance is linked to better glycometabolic management in such ‎individuals. The introduction of direct acting analogues (DAAs) in the previous decade ‎has resulted in a significant improvement in the management of chronic hepatitis C ‎infection. Until date, there has been a scarcity of research on the effects of these drugs ‎on vitamin D (VD), lipid profile, and insulin resistance (IR)‎.‎
Patients and Methods: ‎‎‎ In between April 2019 to February 2020, a cross sectional study was conducted on 100 ‎patients with known chronic hepatitis infection and was eligible to therapy with DAAs. ‎Lipid profile, vitamin D and insulin resistance was assessed at baseline and 3-months ‎after therapy‎.‎
Results: Ninety percent of enrolled patients achieved sustained viral response (SVR). There were no significant changes in lipid ‎profile after therapy with DAAs but at the same time IR was significantly decreased while VD was significantly increased.
Conclusion: Therapy with DAAs is effective in achievement of SVR and also, ‎it could have beneficial effects on insulin resistance and vitamin D. Long term ‎prospective studies on large scale are needed‎‎‎‎‎‎‎‎‎.